Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:600196)

SHA:600196 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	42,731	41,662	41,067	41,400	43,952	39,011
Revenue Growth	8.05%	1.45%	-0.80%	-5.81%	12.66%	28.72%
Gross Profit Gross Profit Growth	21,759	20,784	19,641	19,683	20,696	18,717
Operating Income Operating Income Growth	2,971	2,790	2,974	1,184	3,420	2,537
Net Income Net Income Growth	3,515	3,371	2,770	2,385	3,731	4,729
Earnings Per Share EPS Growth	1.33	1.27	1.04	0.89	1.43	1.85
EPS Growth	7.46%	22.44%	16.10%	-37.52%	-22.50%	29.10%

Revenue by Segment

Chart

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Pharmaceutical Manufacturing Pharmaceutical Manufacturing Growth	29,953	29,274	30,693	31,767	29,212
Health care Service Health care Service Growth	7,395	7,673	6,715	6,158	4,188
Others Others Growth	209.29	191.7	151.06	156.25	81.8
Medical Devices and Medical Diagnosis Medical Devices and Medical Diagnosis Growth	4,340	4,352	4,444	7,254	5,973
Eliminations Eliminations Growth	-235.86	-423.58	-603.39	-1,383	-444.36
Total Total Growth	41,662	41,067	41,400	43,952	39,011

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	15,757	15,358	16,120	15,582	17,170	14,558
Total Debt Total Debt Growth	41,182	36,427	36,021	35,035	30,191	25,454
Net Cash (Debt) Net Cash Growth	-25,425	-21,069	-19,901	-19,453	-13,021	-10,896
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-9.65	-7.96	-7.45	-7.29	-4.99	-4.25

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	5,259	5,213	4,477	3,414	4,218	3,938
Capital Expenditures CapEx Growth	-5,546	-4,448	-4,410	-5,337	-5,889	-4,973
Free Cash Flow Free Cash Flow Growth	-287.92	764.78	66.79	-1,922	-1,671	-1,035
Free Cash Flow Growth	-	1045.04%	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	50.92%	49.89%	47.83%	47.54%	47.09%	47.98%
Operating Margin	6.95%	6.70%	7.24%	2.86%	7.78%	6.50%
Pretax Margin	12.06%	12.27%	10.15%	7.89%	10.41%	15.49%
Profit Margin	8.22%	8.09%	6.74%	5.76%	8.49%	12.12%
FCF Margin	-0.67%	1.84%	0.16%	-4.64%	-3.80%	-2.65%

Dividends

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Dividend Per Share Dividend Per Share Growth	0.390	0.390	0.320	0.270	0.420	0.560
Dividend Per Share Growth	21.88%	21.88%	18.52%	-35.71%	-25.00%	30.23%
Dividend Yield	1.72%	1.58%	1.42%	1.17%	1.29%	1.26%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	17.04	19.31	21.57	25.82	23.30	24.08
Forward PE	41.58	34.77	21.15	21.49	19.36	20.43
P/FCF Ratio	-	85.12	894.58	-	-	-
PS Ratio	1.30	1.56	1.46	1.49	1.98	2.92

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 31, 2026

Data Sources Report a data error